Researchers Discover Potential Functional Role of Genetic Variation in Prostate Cancer Risk
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: 2 minutes
Researchers have described how a common genetic variation may be involved in the development of prostate cancer. The variant occurs in a gene known to be involved in prostate function.
The study, which included a team of researchers at the National Cancer Institute (NCI), part of the National Institutes of Health, uncovered how a small change in the DNA of the gene impacts the biology of prostate cancer risk. The study was published online April 20, 2009, in Proceedings of the National Academy of Sciences.
Differences in the sequence of DNA among individuals are called genetic variations, and some known variations have been associated with an increased risk of certain diseases, such as prostate cancer. The most common type of genetic variation is a change in a single nucleotide, or base, which is one of the building blocks of DNA.
Such single-nucleotide polymorphisms (SNPs) are used in genome-wide association studies of large numbers of individuals with and without a disease to identify DNA regions that are associated with the disease. Although previous studies have identified regions of the genome that are associated with prostate cancer risk, this study was one of the first to explain the biological mechanism underlying the difference in risk among individuals.
Recently, two independent genome-wide association studies of chromosomal regions associated with prostate cancer risk identified a SNP located in a region of chromosome 10 that plays a role in the expression of the gene MSMB. This gene produces a protein that is a potential biomarker for prostate cancer and may also act as a tumor suppressor protein. Previous research has shown that the expression of MSMB declines progressively as prostate cancer advances from early to late stages.
In the new study, the team investigated how the SNP may be related to MSMB function and the development of prostate cancer. They first verified that the SNP is associated with prostate cancer risk. To do so, they compared a region of chromosome 10 that included the SNP and MSMB in blood samples collected from 6,118 men with prostate cancer and 6,105 men without prostate cancer from NCI's Cancer Genetic Markers of Susceptibility (CGEMS) project. This analysis confirmed the strong association of the SNP with prostate cancer.
The team next examined how the two identified variants, or alleles, of the SNP affected the expression of MSMB. The SNP is found as either a C allele or a T allele. This means that some people may have a thymine (T) base at that place in their DNA, whereas other people have a cytosine (C) at that location.
The researchers found that the T allele (the allele that was more common in prostate cancer patients) was associated with lower expression of MSMB than the C allele. Further analyses showed that the transcription factor CREB-a protein that plays a role in turning on gene expression-binds strongly to the C allele but does not bind to the T allele, which lacks a CREB binding site. The team also found that no other SNP within the MSMB region seemed to play a role in the expression of the gene.
"There is mounting evidence that the T allele is associated with prostate cancer risk and decreased expression of MSMB," said study author Meredith Yeager, Ph.D., of NCI's Division of Cancer Epidemiology and Genetics. "The difference observed between the C and T alleles explains the majority of the change in prostate cancer risk observed in the genome-wide association study. However, more work is necessary to say that the T allele is directly causing prostate cancer and to determine if other genetic variations also contribute to this risk."
"This important finding about biological function associated with prostate cancer risk demonstrates the power of genome-wide association studies to provide new and unexpected insights into the genetic underpinnings of cancer etiology," said Joseph F. Fraumeni, Jr., M.D., director of the Division of Cancer Epidemiology and Genetics.
The study, which included a team of researchers at the National Cancer Institute (NCI), part of the National Institutes of Health, uncovered how a small change in the DNA of the gene impacts the biology of prostate cancer risk. The study was published online April 20, 2009, in Proceedings of the National Academy of Sciences.
Differences in the sequence of DNA among individuals are called genetic variations, and some known variations have been associated with an increased risk of certain diseases, such as prostate cancer. The most common type of genetic variation is a change in a single nucleotide, or base, which is one of the building blocks of DNA.
Such single-nucleotide polymorphisms (SNPs) are used in genome-wide association studies of large numbers of individuals with and without a disease to identify DNA regions that are associated with the disease. Although previous studies have identified regions of the genome that are associated with prostate cancer risk, this study was one of the first to explain the biological mechanism underlying the difference in risk among individuals.
Recently, two independent genome-wide association studies of chromosomal regions associated with prostate cancer risk identified a SNP located in a region of chromosome 10 that plays a role in the expression of the gene MSMB. This gene produces a protein that is a potential biomarker for prostate cancer and may also act as a tumor suppressor protein. Previous research has shown that the expression of MSMB declines progressively as prostate cancer advances from early to late stages.
In the new study, the team investigated how the SNP may be related to MSMB function and the development of prostate cancer. They first verified that the SNP is associated with prostate cancer risk. To do so, they compared a region of chromosome 10 that included the SNP and MSMB in blood samples collected from 6,118 men with prostate cancer and 6,105 men without prostate cancer from NCI's Cancer Genetic Markers of Susceptibility (CGEMS) project. This analysis confirmed the strong association of the SNP with prostate cancer.
The team next examined how the two identified variants, or alleles, of the SNP affected the expression of MSMB. The SNP is found as either a C allele or a T allele. This means that some people may have a thymine (T) base at that place in their DNA, whereas other people have a cytosine (C) at that location.
The researchers found that the T allele (the allele that was more common in prostate cancer patients) was associated with lower expression of MSMB than the C allele. Further analyses showed that the transcription factor CREB-a protein that plays a role in turning on gene expression-binds strongly to the C allele but does not bind to the T allele, which lacks a CREB binding site. The team also found that no other SNP within the MSMB region seemed to play a role in the expression of the gene.
"There is mounting evidence that the T allele is associated with prostate cancer risk and decreased expression of MSMB," said study author Meredith Yeager, Ph.D., of NCI's Division of Cancer Epidemiology and Genetics. "The difference observed between the C and T alleles explains the majority of the change in prostate cancer risk observed in the genome-wide association study. However, more work is necessary to say that the T allele is directly causing prostate cancer and to determine if other genetic variations also contribute to this risk."
"This important finding about biological function associated with prostate cancer risk demonstrates the power of genome-wide association studies to provide new and unexpected insights into the genetic underpinnings of cancer etiology," said Joseph F. Fraumeni, Jr., M.D., director of the Division of Cancer Epidemiology and Genetics.
